<?xml version="1.0" encoding="UTF-8"?>
<NDC>
<NDCCode>
12714-196-50
</NDCCode>
<PackageDescription>
50 mg in 1 VIAL, SINGLE-DOSE (12714-196-50)
</PackageDescription>
<NDC11Code>
12714-0196-50
</NDC11Code>
<ProductNDC>
12714-196
</ProductNDC>
<ProductTypeName>
DRUG FOR FURTHER PROCESSING
</ProductTypeName>
<ProprietaryName/>
<ProprietaryNameSuffix/>
<NonProprietaryName>
Idarucizumab
</NonProprietaryName>
<DosageFormName>
LIQUID
</DosageFormName>
<RouteName/>
<StartMarketingDate>
20151021
</StartMarketingDate>
<EndMarketingDate/>
<MarketingCategoryName>
DRUG FOR FURTHER PROCESSING
</MarketingCategoryName>
<ApplicationNumber/>
<LabelerName>
Boehringer Ingelheim Pharma GmbH and Co. KG
</LabelerName>
<SubstanceName>
IDARUCIZUMAB
</SubstanceName>
<StrengthNumber>
50
</StrengthNumber>
<StrengthUnit>
mg/50mg
</StrengthUnit>
<Pharm_Classes/>
<DEASchedule/>
<Status>
Unfinished
</Status>
<LastUpdate>
2023-05-04
</LastUpdate>
<PackageNdcExcludeFlag/>
<ProductNdcExcludeFlag/>
<ListingRecordCertifiedThrough>
20241231
</ListingRecordCertifiedThrough>
<StartMarketingDatePackage>
21-OCT-15
</StartMarketingDatePackage>
<EndMarketingDatePackage/>
<SamplePackage/>
</NDC>